The clinical efficacy of Her ba Clinopodii Tablets combined with dydrogesterone in the treatment of patients with dysfunctional uterine bleeding and their effects on coagulation function and sex hormone indicators
Objective To investigate the clinical efficacy of Herba Clinopodii Tablets combined with dydrogesterone in the treatment of dysfunctional uterine bleeding(DUB)patients and their effects on coagulation function and sex hormone indicators.Methods A total of 98 DUB patients admitted to Pan'an County People's Hospital from March 2019 to January 2022 were selected as the research subjects.They were randomly divided into a control group and an observation group using a random number table method,with 49 patients in each group.The control group was treated with dydrogesterone tablets,while the observation group was treated with dydrogesterone tablets combined with Herba Clinopodii Tablets.The clinical efficacy,clinically relevant indicators,coagulation function indicators,and sex hormone indicators were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P＜0.05).After treatment,both groups showed a decrease in the uterine bleeding scores and endometrial thickness,with the observation group having lower uterine bleeding scores and thinner endometrial thickness than the control group(P＜0.05).After treatment,the activated prothrombin time(aPTT)and prothrombin time(PT)were both shortened in both groups,and the aPTT and PT in the observation group were both shorter than those in the control group(P＜0.05).After treatment,follicle stimulating hormone(FSH),luteinizing hormone(LH),and estradiol(E2)all decreased in both groups,and the FSH,LH,and E2 levels in the observation group were all lower than those in the control group(P＜0.05).Conclusions The combination of Herba Clinopodii Tablets and dydrogesterone has a good clinical efficacy in the treatment of DUB patients,which can enhance hemostasis,improve coagulation function and sex hormone indicators.
万方数据
维普
